What if kidney disease could be treated before it progresses to failure? @archbiopartners.com is advancing research into IL-32, a promising biological pathway linked to diabetic kidney disease, transforming patient care. @amdiabetesassn.bsky.social #ADASciSessions https://youtu.be/S9CppOv643s

Arch Biopartners is featured in the ADA Thought Leadership Series at the 2026 Scientific Sessions. Watch “Advancing Therapies for Diabetic Kidney Disease” (IL-32 and DKD): youtu.be/S9CppOv643s #DKD #CKD #KidneyCare @websedgemedicine.bsky.social News: www.archbiopartners.com/investor-hub...

🚨 Royal Columbian Hospital (RCH), part of @fraserhealth.ca, has dosed its first patient in Arch Biopartners’ Phase II CS-AKI trial evaluating LSALT peptide. RCH is the 4th dosing site in Canada. 📖 www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky #peptide #kidneycare

Dr. Justin Chun presents at the CSN AGM May 8, 9:45 AM (Québec City) on patient-derived kidney organoids, touching on IL-32 disease models + bioengineering strategies to advance kidney organoid models. 🔗 agm.csnscn.ca #NephSky #Nephrology

🚨 Royal Columbian Hospital (RCH), part of @fraserhealth.ca, has begun patient recruitment in Arch Biopartners’ Phase II CS-AKI trial evaluating LSALT peptide. RCH is the 4th recruiting site in Canada. 📖 Read the full release: www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky

Congrats! Arch CKD lead Drs. Justin Chun and Arch CSO Daniel Muruve @ucalgarymed.bsky.social on new findings that suggest distinct lipid signatures may act as pathological indicators in glomerular kidney disease, with potential diagnostic and mechanistic insight. iopscience.iop.org/article/10.1...

📰 The Clinical Trial Vanguard article reporting on Arch Biopartners ongoing Phase II LSALT Trial, Clinical Trial Updates www.clinicaltrialvanguard.com/news/patient...

🚨 Arch announced @fraserhealth.ca has entered into a Clinical Trial Agreement with the Company to enable Royal Columbian Hospital to prepare for recruitment in the Phase II CS-AKI trial evaluating LSALT peptide. 📖 www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky

🚨 Arch Biopartners: St. Michael’s Hospital (Unity Health Toronto) has commenced patient dosing in the Phase II CS-AKI trial of LSALT peptide. 🧪 News also provides ongoing Phase II clinical trials updates. 📖 Full release: www.archbiopartners.com/investor-hub... #AKI #CSAKI #NephSky

📰 Streetwise Reports featured Arch Biopartners in a contributed technical analyst opinion discussing the company’s kidney-focused pipeline and recent public disclosures. 🔗 Read the full report here: www.streetwisereports.com/article/2026... #ArchNews #BiotechNews

🚨 New peer-reviewed publication in Inflammation Research identifies IL-32 as a lipid droplet-associated cytokine linked to tubular injury in DKD. The findings strengthen the scientific foundation for Arch Biopartners’ CKD Platform targeting IL-32 📖 archbiopartners.com/investor-hub #CKD #NephSky

🚨 Arch Biopartners announced the appointment of Dr. Patrick Vink, M.D., M.B.A., as Chairman of the Board, effective January 15, 2026. Dr. Vink brings extensive experience in global pharmaceutical leadership and governance. 📖 Full release: archbiopartners.com/investor-hub #ArchBiopartners #ArchNews

🚨 Boehringer Ingelheim and Rectify Pharma outlined a $448M deal for a preclinical CKD program. www.fiercebiotech.com/biotech/boeh... Arch is advancing a CKD platform targeting IL-32. 🔬 archbiopartners.com/our-science #Biotech #CKD

🚨 Arch Biopartners announced that St. Michael’s Hospital @unityhealthto.bsky.social received ethics approval to join the Phase II CS-AKI trial evaluating LSALT peptide. 🏥 4th Canadian site, 9th globally. 🔗 Read more (and share): www.archbiopartners.com/arch-biopart... #LSALTpeptide #AKI #CSAKI

🔎 A Pediatric Nephrology study (@ped-neph.bsky.social link.springer.com/article/10.1007/s00467-023-06197-1) shows machine learning can help predict AKI in children after heart surgery. Arch’s trials are evaluating drugs to prevent AKI in high-risk patients. 🔬 archbiopartners.com/our-science #CSAKI

📚 JACC: Heart Failure (www.jacc.org/doi/10.1016/j.jchf.2024.11.007): CKD in U.S. veterans with heart failure raised hospitalization and death risk across all ejection fractions. Underscores need for targeted CKD therapies. 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #NephSky

📈 As CKD cases continue to rise in Canada, The Kidney Foundation is calling for a National CKD Framework at kidney.ca/Get-Involved/Advocacy/National-CKD-Framework Arch is advancing CKD therapeutics developed in Calgary. 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #NephSky

📈 GBD study @thelancet.com, CKD in top 10 causes of death. @ctvnewscalgary.bsky.social reports cases have doubled in Canada www.ctvnews.ca/video/2025/12/01/ctv-national-news-more-canadians-living-with-chronic-kidney-disease/ 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #NephSky

🧬 2023 Antioxidants review www.mdpi.com/2076-3921/12... links oxidative stress to AKI, CKD, and cardiovascular risk. Arch is advancing Phase II trials targeting inflammation and injury before kidney damage is irreversible. 🔬 archbiopartners.com/our-science/lsaltpeptide #AKI #KidneyCare #NephSky

📚 Nov 2025 study in JCVA jcvaonline.com/article/S1053-0770(25)00632-9/fulltext In >1,000 cardiac surgery patients, elevated hemolysis index, and longer bypass time predicted AKI. Supports inflammation-targeted CS-AKI therapies. 🔬 archbiopartners.com/our-science/lsaltpeptide/ #CSAKI #LSALTpeptide

📚 KDIGO 2022 guideline - @theisn.org - www.kidney-international.org/article/S008... Managing diabetic CKD is complex and current treatments rely on broad effects. On-target approaches are needed. 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #NephSky

📚 A 2022 Kidney International Supplement @theisn.org - www.kisupplements.org/article/S215... shows rising CKD rates and gaps in diagnosis and treatment. More precise, pathway-focused therapies are needed. 🔬 archbiopartners.com/our-science/ckd-platform/ #CKD #KidneyCare #NephSky

📚 @thelancet.com study - www.thelancet.com/journals/lan... - confirms CKD has entered the top 10 causes of death worldwide. Arch is advancing IL-32–targeting drug candidates to address chronic kidney disease at the source. 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #NephSky

🧪 A Life Sciences review (www.sciencedirect.com/science/arti...) confirms that inflammation, vascular injury, and mitochondrial damage drive S-AKI. These same mechanisms are also active in cardiac surgery-associated AKI (CS-AKI). 🔬 archbiopartners.com/our‑science/lsaltpeptide#AKIK#CSAKIK#NephSkyky

📈 A 2025 study in NDT (doi.org/10.1093/ndt/gfaf084) found high kidney failure & mortality rates in IgA nephropathy. Arch’s CKD platform targets IL-32, a cytokine linked to kidney inflammation, complementing its AKI platform. 🔬 archbiopartners.com/our-science/ckd-platform/ #CKD #KidneyCare #NephSky

📚 An AKI case in @cureusmedical.bsky.social (doi.org/10.7759/cureus.88144) shows how difficult diagnosis can be without clear criteria. Arch’s ongoing Phase II trial for CS-AKI uses KDIGO to guide consistent diagnosis. 🔬 archbiopartners.com/our-science/lsaltpeptide #AKI #CSAKI #KDIGO #NephSky

🧬 Frontiers in Nephrology (doi.org/10.3389/fneph.2024.1436896) examines chemotherapy-related AKI. Arch is supporting an ongoing Phase II trial of cilastatin to prevent drug-induced AKI. 🔬 archbiopartners.com/our-science/cilastatin #AKI #Cilastatin #NephSky #KidneyCare @frontiersin.bsky.social

🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI. 📖 Latest News at www.archbiopartners.com/investor-hub/ #AKI #CSAKI #KidneyCare #NephSky

🧬 @springernature.com - nature.com/articles/s41598-025-18475-z finds DPEP1 blocks NK-cell killing in colon cancer. LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration. archbiopartners.com/our-science #NephSky #DPEP1

🚨 Novo Nordisk to acquire Akero Therapeutics in a $5.2B deal, expanding its MASH & metabolic portfolio with a Phase 3 FGF21 analogue @barrons.com: bit.ly/akero-novo-nordisk Arch develops on-target drugs for AKI & CKD, a condition tied to metabolic dysfunction. 🔬 archbiopartners.com/about-us #Biotech

🚨 Omeros jumps 154% after Novo Nordisk signs a $2.1B deal for Zaltenibart, now in testing for PNH and related kidney disorders. @ibdinvestors.bsky.social: bit.ly/omeros-novo-... Arch Biopartners is developing on-target drugs for AKI and CKD. 🔬 archbiopartners.com/about-us #Biotech #CKD #NephSky

A 2023 review (www.seminarsinnephrology.org/article/S027... shows how cisplatin causes AKI through inflammation, oxidative stress, and cell injury. Learn more about the Phase II trial evaluating cilastatin to protect kidneys. 🔬 archbiopartners.com/our-science/cilastatin #AKI #Cilastatin #NephSky

📉 Kidney Medicine @kidneymed.bsky.social (Dec 2024): Cilastatin was linked to a 74% lower AKI risk in clinical trials, 46% in observational studies. Overall: 48%. Arch is supporting the PONTiAK Phase II trial, now recruiting. 🔬 archbiopartners.com/our-science/cilastatin #Cilastatin #AKI #NephSky

📚 @frontiersin.bsky.social 2025 (doi.org/10.3389/fendo.2025.1513008): CKD mortality due to diabetes has nearly tripled since 1990 and is projected to continue rising. Highlights need for on-target CKD treatments. 🔬 archbiopartners.com/our-science/ckd-platform #CKD #KidneyCare #Nephsky

🌍 @sciam.bsky.social (bit.ly/sci-american...) highlights the global CKD burden and the need for better detection. Heat stress is one factor under study. Arch Biopartners has launched a CKD platform, complementing two Phase II AKI trials. 🔬 archbiopartners.com/our-science #CKD #AKI #NephSky

📚 Lancet Reg Health – Americas (www.thelancet.com/journals/lan... CKD affects 27% of people with type 1 diabetes in a U.S. cohort; >10% face severe disease. Highlights urgent need for precise CKD therapies. 🔬 archbiopartners.com/our-science/ckd-platform #ArchBiopartners #CKD #NephSky

📚 CDC, 2023 (cdc.gov/kidney-disease/php/data-research/): Over 35 million U.S. adults (more than 1 in 7) have CKD. The data highlights the epidemic scale of the disease and need for on-target CKD treatments. 🔬New CKD platform: archbiopartners.com/our-science/ckd-platform/ #CKD #KidneyCare #NephSky

🚨 Fierce Biotech: “Sparrow flies with $95M for midstage diabetes asset” (fiercebiotech.com/biotech/sparrow-flits-forward-95m-series-b-midstage-diabetes-asset). Arch Biopartners is a therapeutic biotech with 2 Phase II AKI programs and preclinical IP in CKD. 🔬 archbiopartners.com/our-science/

📚 @frontiersin.bsky.social Cardiovasc. Med. (doi.org/10.3389/fcvm.2023.1108538) - 1 in 5 adults with CS-AKI develop CKD within 90 days. Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform. 🔬 archbiopartners.com/our-science #CKD #CSAKI #LSALTpeptide #NephSky

📚 Nature Reviews: Nephrology (doi.org/10.1038/s41581-024-00820-6): CKD affects more than 800M people globally, steep increase for 2030. Arch is a kidney therapeutics company with a CKD platform and two ongoing Phase II AKI trials. 🔬 archbiopartners.com/our-science/ckd-platform/ #CKD #AKI #NephSky

🚨 Fierce: “Sanofi juices up biotech investment arm with $625M” (bit.ly/sanofi-625m-cash-infusion). Arch is a therapeutic biotech with two Phase II programs for AKI and preclinical IP advancing kidney therapeutics in CKD. 🔬 archbiopartners.com/our-science/ #AKI #CKD #BiotechNews #NephSky

🧬 2024 @springernature.com Scientific Reports study (nature.com/articles/s41598-024-67020-x) found DI-AKI from anticancer drugs has a ~23.6% fatality rate, rising sharply after 2010. Cilastatin is in a Phase II trial for DI-AKI. 🔬 archbiopartners.com/our-science/cilastatin #AKI #Cilastatin #NephSky

📚 National Geographic reports a 90% rise in CKD since 1990 (nationalgeographic.com/health/article/chronic-kidney-disease-rise). Arch has announced a CKD platform targeting diabetic CKD, complementing two ongoing Phase II AKI trials. 🔬 archbiopartners.com/our-science #CKD #NephSky #KidneyCare

🚨 Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD). 🔬 Full News Release: archbiopartners.com/investor-hub/press-releases/ #KidneyCare #CKD #NephSky #ArchBiopartners

📚 A 2025 review confirms KDIGO 2012 as the leading AKI guideline (doi.org/10.3389/fmed.2025.1567359). Arch Biopartners’ Phase II trial for CS‑AKI uses KDIGO to define AKI after cardiac surgery. 🔬 archbiopartners.com/our-science/metablok #AKI #CSAKI #NephSky #ArchScience #LSALTpeptide

📊 A 2022 study in Kidney International (doi.org/10.1016/j.kint.2022.02.033) showed consistent AKI incidence and outcomes across Canada, Denmark, and the UK using harmonized KDIGO definitions. Supports the need for targeted kidney therapies. 🔬 archbiopartners.com/our-science #AKI #CSAKI #NephSky

📊 A 2025 study in Critical Care @springernature.com (doi.org/10.1186/s13054-025-05351-5) shows nearly half of ICU patients with sepsis develop AKI. Arch is supporting two Phase II trials focused on CS-AKI and DI-AKI. 🔬 archbiopartners.com/our-science #AKI #KidneyCare #NephSky #ArchBiopartners

A 2024 Frontiers review (doi.org/10.3389/fimmu.2024.1353339) shows how cancer immunotherapies can trigger acute kidney injury (AKI). Part of a 2025 research topic highlighting AKI and the urgent need for kidney protection. 🔬 archbiopartners.com/our-science #AKI #KidneyCare #ArchScience #NephSky

Frontiers cohort study (doi.org/10.3389/fmed.2024.1459170), part of a research topic, maps hospital drug classes linked to drug-induced acute kidney injury (DI-AKI). PONTIAK Phase II trial of cilastatin to prevent DI-AKI now recruiting. 🔬 archbiopartners.com/cilastatin #AKI #Cilastatin #NephSky

March 2025 Frontiers in Medicine case series (doi.org/10.3389/fmed.2025.1495705), part of a research topic, reports dialysis rescue after methotrexate-induced AKI. Arch is supporting a Phase II trial of cilastatin for kidney protection. 🔬 archbiopartners.com/cilastatin #AKI #Cilastatin #KidneyCare